| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8959203 | Transplantation Proceedings | 2018 | 26 Pages |
Abstract
These data support the notion that azacitidine is best used as a preemptive therapy against relapse for patients after allo-HSCT performed for myeloid malignancy. Applying azacitidine as therapy for ongoing relapse after allo-HSCT may lead to stable disease and allow for better performance of the second allo-HSCT.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
E. Karakulska-Prystupiuk, J. Drozd-SokoÅowska, A. Waszczuk-Gajda, A. Stefaniak, J. Dwilewicz-Trojaczek, A. Kulikowska, E. ChmarzyÅska-Mróz, G. Basak, M. Paluszewska, P. Boguradzki, W. JÄdrzejczak,